Evidence map›Paper›PMID 39380104›Full record

ArticleStem cell research & therapy2024

CGF therapy: bridging androgenetic alopecia observations to psoriasis treatment via IL-17 pathway.

Qin Xiao, Weifang Chu, Jing Guo, Jin Gao, Wei Yao, Minghuan Huang, Yongzhou Lu, Qiannan Xu, Nan Xu

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Treatment for Filler-Induced Alopecia with Concentrated Growth Factors.Clinical, cosmetic and investigational dermatology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qin Xiao *Department of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China.
Weifang Chu *Department of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China.
Jing Guo *Department of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China.
Jin GaoDepartment of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China.
Wei YaoDepartment of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China.
Minghuan HuangDepartment of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China.
Yongzhou LuDepartment of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China. drluther@163.com.
Qiannan XuDepartment of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China. greatfuturedoctor@hotmail.com.ORCID 0000-0003-0707-7441
Nan XuDepartment of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China. xnhrb1320@sohu.com.

Funding

Central University Basic Research Fund of China 22120240377East Hospital Young Doctor Incubation Fund Project YDNT-FP002National Natural Science Foundation of China 82202018Shanghai Pudong New Area Health Committee Supervision Institute PWZzb2022-19Youth Research and Cultivation Fund of East Hospital 2023019
6 · The paper itself

Abstract

introductionConcentrated Growth Factor (CGF), rich in CD34 + stem cells, is widely used in treatments for androgenetic alopecia and skin rejuvenation due to its immune-modulating properties. Psoriasis, a chronic inflammatory skin condition, presents significant treatment challenges, particularly for patients who cannot use biologics due to conditions such as cancer and lesions resistant to treatments. The potential of CGF in treating psoriasis is promising, given its broad immunoregulatory effects which confirmed in our previous androgenetic alopecia work.

methodsWe evaluated the impact of CGF on IL-17 levels in two contexts: patients treated for androgenetic alopecia and a psoriasis mouse model. Twelve patients received three monthly injections of CGF, with serum IL-17 levels measured before and after treatment. In the psoriasis mouse model, groups were treated with CGF, and outcomes were assessed using the Psoriasis Area and Severity Index (PASI), skin barrier scores, histological analysis, and RNA sequencing. Additionally, in vitro experiments applied CD34 + cells from CGF to keratinocytes to measure levels of TNF-α, IFN-γ, IL-23, and IL-17.

resultsIn patients with androgenetic alopecia, three monthly CGF injections resulted in significantly reduced serum IL-17 levels. In the psoriatic mouse model, CGF-treated groups exhibited lower PASI scores and improved skin barrier scores compared to controls. Histological analysis revealed enhanced skin characteristics, while RNA sequencing demonstrated downregulated IL-17 and upregulated CD34 expression, as well as improved expression of barrier-related genes. In vitro, the application of CD34 + cells from CGF to keratinocytes led to a significant reduction in TNF-α, IFN-γ, IL-23, and IL-17 levels, indicating strong anti-inflammatory effects. A clinical case of a psoriasis patient unresponsive to IL-23 therapy (Guselkumab) showed significant improvement following CGF treatment.

conclusionThese findings indicate that CGF could serve as an effective and versatile treatment for psoriasis, especially for patients who have already undergone biologic therapies but continue to experience resistant lesions.

Indexed as

AlopeciaInterleukin-17PsoriasisAdultAnimalsAntigens, CD34Disease Models, AnimalFemaleHumansIntercellular Signaling Peptides and ProteinsMaleMiceMiddle AgedAntigens, CD34Intercellular Signaling Peptides and ProteinsInterleukin-17CD34CGFIL-17PsoriasisStem cell

Identifiers

PMID39380104
PMCPMC11462746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.